论文部分内容阅读
目的:制备P物质(Substance P,SP)PLGA(poly lactide-co-glycolide)纳米缓释微粒,考察其性质及体外释药特性。方法:以PLGA为载体,应用复乳-溶剂挥发法制备P物质缓释纳米粒,并运用酶联免疫吸附法(ELISA)测定其载药率、包封率及体外释药特性。结果:P物质缓释纳米微粒球体均匀度好,平均粒径22.32±5.41 nm,载药纳米球的载药率(0.66±0.036)%;包封率为(66.28±3.56)%。纳米粒体外释药突释期累积释放率为28.65%,12 d后释放率为77.46%。结论:建立了较好的P物质PLGA纳米缓释微粒粉制备工艺,载药纳米微粒体外具有明显缓释特性。
OBJECTIVE: To prepare the sustained-release nanoparticles of polylactide-co-glycolide (PLGA) with substance P (SP) and study its properties and in vitro release characteristics. Methods: PLGA was used as carrier to prepare drug substance P nanoparticles by double emulsion - solvent evaporation method. The drug loading rate, entrapment efficiency and in vitro drug release characteristics were determined by enzyme - linked immunosorbent assay (ELISA). Results: The microspheres of substance P sustained-release nanoparticles had good uniformity with average particle size of 22.32 ± 5.41 nm and drug-loaded nanospheres loading rate of 0.66 ± 0.036%. The encapsulation efficiency was (66.28 ± 3.56)%. The cumulative release rate of the nanoparticles during in vitro release was 28.65%, and the release rate was 77.46% after 12 days. CONCLUSION: A better preparation process of nanoparticle of substance P nanoparticles was established. The drug-loaded nanoparticles have obvious sustained-release characteristics in vitro.